A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

Inclusion Criteria:

• Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²)

• Males who agree to follow contraceptive requirements and women of not childbearingpotential

• Have body weight greater than or equal to (>=) 50 Kilograms at screening.

• Must have a negative Interferon-Gamma Release Assays (IGRA) testing at screening

• Must have been stopped all the prescribed medication at least 14 days prior toadmission to the clinical site

• Ability and willingness to abstain from alcohol, caffeine, andmethylxanthine-containing beverages or food 2 days prior to admission to theclinical site

• Abstain from any strenuous physical exercise from 4 days prior to admission andduring confinement at the clinical site

Exclusion Criteria:

• Have a history of relevant drug and/or food allergies, or sensitivity to medicationsused in the current study

• Females participants who are currently breastfeeding

• Have History of alcohol abuse or drug addiction

• Unable to abstain from tobacco products within the 2 days prior to admission andduring confinement at the clinical site

• Have Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV)antibodies, or human immunodeficiency virus (HIV) 1 and 2 antibodies

• Consumption of any nutrients known to modulate CYP450 enzymes activity

• Are immunocompromised

• Have received live vaccine(s) (including attenuated live vaccines) or BacillusCalmette-Guérin within 28 days of screening or intend to receive them during thestudy

• Have had any malignancy within the past 5 years